These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 21726569)

  • 1. Mouse pharmacological models of cognitive disruption relevant to schizophrenia.
    Young JW; Powell SB; Geyer MA
    Neuropharmacology; 2012 Mar; 62(3):1381-90. PubMed ID: 21726569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.
    Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically.
    Brown JW; Rueter LE; Zhang M
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Mar; 49():53-62. PubMed ID: 24269664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NMDA receptors, cognition and schizophrenia--testing the validity of the NMDA receptor hypofunction hypothesis.
    Gilmour G; Dix S; Fellini L; Gastambide F; Plath N; Steckler T; Talpos J; Tricklebank M
    Neuropharmacology; 2012 Mar; 62(3):1401-12. PubMed ID: 21420987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postnatal Phencyclidine (PCP) as a Neurodevelopmental Animal Model of Schizophrenia Pathophysiology and Symptomatology: A Review.
    Grayson B; Barnes SA; Markou A; Piercy C; Podda G; Neill JC
    Curr Top Behav Neurosci; 2016; 29():403-428. PubMed ID: 26510740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral animal models to assess pro-cognitive treatments for schizophrenia.
    Young JW; Amitai N; Geyer MA
    Handb Exp Pharmacol; 2012; (213):39-79. PubMed ID: 23027412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Animal models of schizophrenia.
    Jones CA; Watson DJ; Fone KC
    Br J Pharmacol; 2011 Oct; 164(4):1162-94. PubMed ID: 21449915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCP-induced deficits in murine nest building activity: employment of an ethological rodent behavior to mimic negative-like symptoms of schizophrenia.
    Pedersen CS; Sørensen DB; Parachikova AI; Plath N
    Behav Brain Res; 2014 Oct; 273():63-72. PubMed ID: 25064467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MK-801 and amphetamine result in dissociable profiles of cognitive impairment in a rodent paired associates learning task with relevance for schizophrenia.
    Talpos J; Aerts N; Waddell J; Steckler T
    Psychopharmacology (Berl); 2015 Nov; 232(21-22):3911-20. PubMed ID: 25902874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative.
    Carter CS; Barch DM
    Schizophr Bull; 2007 Sep; 33(5):1131-7. PubMed ID: 17630405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.
    Neill JC; Barnes S; Cook S; Grayson B; Idris NF; McLean SL; Snigdha S; Rajagopal L; Harte MK
    Pharmacol Ther; 2010 Dec; 128(3):419-32. PubMed ID: 20705091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissociated features of social cognition altered in mouse models of schizophrenia: Focus on social dominance and acoustic communication.
    Faure A; Nosjean A; Pittaras E; Duchêne A; Andrieux A; Gory-Fauré S; Charvériat M; Granon S
    Neuropharmacology; 2019 Nov; 159():107334. PubMed ID: 30236964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: Possible involvement of the endocannabinoid system.
    Seillier A; Giuffrida A
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):298-309. PubMed ID: 26706691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hippocampal complexin proteins and cognitive dysfunction in schizophrenia.
    Sawada K; Barr AM; Nakamura M; Arima K; Young CE; Dwork AJ; Falkai P; Phillips AG; Honer WG
    Arch Gen Psychiatry; 2005 Mar; 62(3):263-72. PubMed ID: 15753239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.
    Iwata Y; Nakajima S; Suzuki T; Keefe RS; Plitman E; Chung JK; Caravaggio F; Mimura M; Graff-Guerrero A; Uchida H
    Mol Psychiatry; 2015 Oct; 20(10):1151-60. PubMed ID: 26077694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognition in mouse models of schizophrenia susceptibility genes.
    Arguello PA; Gogos JA
    Schizophr Bull; 2010 Mar; 36(2):289-300. PubMed ID: 20026558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The relationship between cognition and functional outcome in schizophrenia].
    Komlósi S; Czobor P; Bálint S; Bitter I
    Psychiatr Hung; 2008; 23(3):166-76. PubMed ID: 18956623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schizophrenia clues from monkeys.
    Pennisi E
    Science; 1997 Aug; 277(5328):900. PubMed ID: 9281070
    [No Abstract]   [Full Text] [Related]  

  • 19. The NEWMEDS rodent touchscreen test battery for cognition relevant to schizophrenia.
    Hvoslef-Eide M; Mar AC; Nilsson SR; Alsiö J; Heath CJ; Saksida LM; Robbins TW; Bussey TJ
    Psychopharmacology (Berl); 2015 Nov; 232(21-22):3853-72. PubMed ID: 26202612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxytocin and Schizophrenia Spectrum Disorders.
    Ettinger U; Hurlemann R; Chan RCK
    Curr Top Behav Neurosci; 2018; 35():515-527. PubMed ID: 28864974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.